根據一項近期的協議，Abbott實驗室獲得了將Nephromics公司獲得的的檢測和監測先兆子癇的兩種蛋白質，開發成商業化產品的全球準獨家權利。，

Abbott打算開發成為檢測先兆子癇的體外檢測方法。目前對這種危及生命的疾病還沒有特異性的診斷檢測方法，這種疾病每年都危及許多妊娠婦女。Abbott實驗室診斷測試與系統開發副總裁William Brow博士解釋說：“Abbott的目標是開發分娩前檢測方法，能夠用于對妊娠并發癥進行早期的危險分層檢測。”

Abbott具有研發內分泌和其它激素相關檢測方法的歷史；向全球診斷檢測市場的關鍵領域提供范圍廣泛的革新設備系統和檢測方法。

“Because preeclampsia can strike quickly, potentially causing severe and immediate complications such as seizures and organ failure that threaten both the health of the baby and mother unless pregnancy is induced, early diagnostic tests are needed,” observed David Barch, M.D., medical director, Abbott Diagnostics. “These tests would be developed for use on our premier diagnostic analyzer, the Architect integrated immunoassay and clinical chemistry system.”
Abbott診斷公司的醫學主任David Barch說：“因為先兆子癇起病迅速，能夠導致嚴重的并發癥，例如癲癇發作和器官功能衰竭，在妊娠沒有開始之前就會危及嬰兒和母親的健康，因此早期診斷檢測是十分必要的。這些即將研制的檢測方法，將使用我們公司功能強大的診斷分析儀：Architect綜合免疫分析和臨床化學系統。”

Abbott to Develop Preeclampsia Test
 
Under a recent agreement, worldwide semi-exclusive rights to commercialize products using patents of Nephromics (Chestnut Hill, MA, USA) related to two proteins for detecting and monitoring preeclampsia have been granted to Abbott Laboratories (Abbott Park, IL, USA).

Abbott intends to develop an in vitro diagnostic test to detect preeclampsia. There is currently no specific diagnostic test for this life-threatening disease that affects many pregnant women each year. “Abbott’s goal is to develop prenatal tests that could be utilized for early risk stratification of pregnancy complications,” explained William Brown, Ph.D., vice president, diagnostic assays and systems development, Abbott Labs.

Abbott has a history of developing endocrine and other hormone-related tests and offers a broad range of innovative instrument systems and tests across key segments of the global diagnostics market. Immunodiagnostics is a core component of the company’s medical products business.

“Because preeclampsia can strike quickly, potentially causing severe and immediate complications such as seizures and organ failure that threaten both the health of the baby and mother unless pregnancy is induced, early diagnostic tests are needed,” observed David Barch, M.D., medical director, Abbott Diagnostics. “These tests would be developed for use on our premier diagnostic analyzer, the Architect integrated immunoassay and clinical chemistry system.”